() has delivered encouraging results from its phase II clinical study treating stroke patients with its CTX stem cell candidate.
CFO Michael Hunt tells Proactive: ''We're very encouraged by these results. The objective of the study was to see if we could garner a strong enough clinical signal in disabled stroke patients to warrant taking this drug into much larger, pivotal clinical development''.
''I'm pleased to say that the readouts we've had from the study so far have met that objective''.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE